Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Cash, Cash Equivalents, Marketable Securities : HK$2,765.4 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Cash, Cash Equivalents, Marketable Securities?

Sichuan Kelun-Biotech Biopharmaceutical Co's quarterly cash, cash equivalents, marketable securities increased from Dec. 2022 (HK$133.14 Mil) to Jun. 2023 (HK$1,759.60 Mil) and increased from Jun. 2023 (HK$1,759.60 Mil) to Dec. 2023 (HK$2,765.45 Mil).

Sichuan Kelun-Biotech Biopharmaceutical Co's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (HK$145.00 Mil) to Dec. 2022 (HK$133.14 Mil) but then increased from Dec. 2022 (HK$133.14 Mil) to Dec. 2023 (HK$2,765.45 Mil).

Sichuan Kelun-Biotech Biopharmaceutical Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Cash, Cash Equivalents, Marketable Securities Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

145.00

133.14

2,765.45

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			-	414.25	133.14	1,759.60	2,765.45

Sichuan Kelun-Biotech Biopharmaceutical Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Sichuan Kelun-Biotech Biopharmaceutical Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Executives

Liu Gexin	2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Merck & Co., Inc.	2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc	2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si	2101 Beneficial owner
Li Jun	2201 Interest of corporation controlled by you
Zhou Quan	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p.	2201 Interest of corporation controlled by you
Victory Rhythm Limited	2201 Interest of corporation controlled by you
Wealthy Linkage Limited	2101 Beneficial owner
Ho Chi Sing	2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines